Tirdzniecība Biotage - BIOT CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Starpība | 1.7 | ||||||||
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.025632% | ||||||||
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | -0.018813% | ||||||||
Nakts laika nodeva | 22:00 (UTC) | ||||||||
Min. tirgotais daudzums | 1 | ||||||||
Valūta | SEK | ||||||||
Drošības rezerve | 20% | ||||||||
Fondu birža | Sweden | ||||||||
Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Biotage AB ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Iepriekš. aizvērt* | 174.6 |
Atvērt* | 176.8 |
Izmaiņas par 1 gadu* | -6.36% |
Dienas Diapazons* | 175.5 - 178.1 |
52 ned Diapazons | 149.80-239.40 |
Vidējais apjoms (10 dienas) | 56.68K |
Vidējais apjoms (3 mēneši) | 1.75M |
Tirgus Kapitalizācija | 11.69B |
Cenas/Peļņas Attiecība | 49.02 |
Izvietotās Akcijas | 65.98M |
Ieņēmumi | 1.52B |
EPS | 3.61 |
Dividende (Ienesīgums %) | 0.87521 |
Beta | 1.22 |
Nākamās Peļņas Datums | Feb 15, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
---|---|---|---|---|---|---|
Feb 8, 2023 | 176.4 | -0.2 | -0.11% | 176.6 | 178.4 | 174.8 |
Feb 7, 2023 | 174.6 | 1.8 | 1.04% | 172.8 | 174.9 | 170.0 |
Feb 6, 2023 | 173.8 | 0.7 | 0.40% | 173.1 | 174.0 | 171.1 |
Feb 3, 2023 | 174.8 | 6.6 | 3.92% | 168.2 | 175.5 | 166.7 |
Feb 2, 2023 | 170.2 | 5.9 | 3.59% | 164.3 | 171.7 | 163.2 |
Feb 1, 2023 | 161.8 | 1.3 | 0.81% | 160.5 | 163.7 | 159.9 |
Jan 31, 2023 | 159.9 | 1.5 | 0.95% | 158.4 | 160.5 | 157.0 |
Jan 30, 2023 | 160.3 | -0.9 | -0.56% | 161.2 | 161.8 | 157.5 |
Jan 27, 2023 | 161.8 | 2.7 | 1.70% | 159.1 | 162.3 | 159.1 |
Jan 26, 2023 | 160.5 | 3.7 | 2.36% | 156.8 | 162.0 | 156.8 |
Jan 25, 2023 | 158.5 | 1.8 | 1.15% | 156.7 | 158.5 | 154.8 |
Jan 24, 2023 | 157.3 | 1.1 | 0.70% | 156.2 | 162.7 | 155.5 |
Jan 23, 2023 | 156.2 | 1.8 | 1.17% | 154.4 | 157.9 | 153.9 |
Jan 20, 2023 | 152.2 | 1.0 | 0.66% | 151.2 | 153.7 | 147.6 |
Jan 19, 2023 | 152.7 | -2.8 | -1.80% | 155.5 | 157.6 | 150.9 |
Jan 18, 2023 | 156.8 | -7.5 | -4.56% | 164.3 | 165.4 | 152.6 |
Jan 17, 2023 | 172.4 | 1.9 | 1.11% | 170.5 | 172.9 | 168.5 |
Jan 16, 2023 | 173.8 | -1.9 | -1.08% | 175.7 | 176.1 | 170.0 |
Jan 13, 2023 | 175.1 | -1.8 | -1.02% | 176.9 | 177.2 | 171.3 |
Jan 12, 2023 | 170.5 | -3.5 | -2.01% | 174.0 | 175.5 | 169.2 |
Biotage Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Ikgadējs
- Ceturkšņa
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Kopējie ienākumi | 667.912 | 748.147 | 910.896 | 1101.37 | 1092.28 | 1232 |
Ienākumi | 667.912 | 748.147 | 910.896 | 1101.37 | 1092.28 | 1232 |
Cost of Revenue, Total | 282.098 | 291.483 | 354.27 | 415.963 | 425.55 | 477 |
Bruto Peļņa | 385.814 | 456.664 | 556.626 | 685.41 | 666.728 | 755 |
Kopējie Darbības Izdevumi | 568.798 | 614.517 | 738.418 | 893.253 | 886.093 | 961 |
Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 237.338 | 254.497 | 313.127 | 360.028 | 336.94 | 374 |
Pētniecība un Attīstība | 17.326 | 33.581 | 43.101 | 49.733 | 44.102 | 56 |
Depreciation / Amortization | 39.795 | 30.241 | 34.032 | 65.132 | 66.449 | 65 |
Procentu Izdevumi (Ienākumi) - Neto Darbība | -7.004 | -8.309 | -14.681 | -2.41 | -19.352 | -16 |
Neparedzēti Izdevumi (Ienākumi) | 0 | 2.5 | 2.5 | |||
Other Operating Expenses, Total | -0.755 | 13.024 | 6.069 | 2.307 | 32.404 | 5 |
Darbības Izdevumi | 99.114 | 133.63 | 172.478 | 208.12 | 206.185 | 271 |
Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -6.713 | 2.63 | 3.811 | 3.949 | -8.901 | -12 |
Citi, Neto | 0 | 0 | 0 | -0.077 | 25.445 | 10 |
Neto Ienākumi Pirms Nodokļu Nomaksas | 92.401 | 136.26 | 176.289 | 211.992 | 222.729 | 269 |
Neto Ienākumi Pēc Nodokļu Nomaksas | 92.795 | 138.747 | 167.627 | 186.82 | 175.331 | 205 |
Neto Ienākumi Pirms Ārkārtas Posteņiem | 92.795 | 138.747 | 167.627 | 186.82 | 175.331 | 205 |
Neto Ienākumi | 92.795 | 138.747 | 167.627 | 186.82 | 175.331 | 205 |
Total Adjustments to Net Income | 0.001 | |||||
Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | 92.796 | 138.747 | 167.627 | 186.82 | 175.331 | 205 |
Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | 92.796 | 138.747 | 167.627 | 186.82 | 175.331 | 205 |
Atšķaidītie Neto Ienākumi | 92.796 | 138.747 | 167.627 | 186.82 | 175.331 | 205 |
Atšķaidītie Ienākumi par Akcijām | 64.7144 | 64.7144 | 64.7144 | 65.1821 | 65.2085 | 65.4648 |
Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | 1.43393 | 2.14399 | 2.59026 | 2.86612 | 2.68877 | 3.13145 |
Dividends per Share - Common Stock Primary Issue | 1.25 | 1.4 | 1.5 | 0 | 1.5 | 1.55 |
Atšķaidītā Normalizētā Peļņa par Akciju | 1.43393 | 2.14399 | 2.62699 | 2.89992 | 2.68877 | 3.17802 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Kopējie ienākumi | 281.35 | 303.458 | 305 | 342 | 386 |
Ienākumi | 281.35 | 303.458 | 305 | 342 | 386 |
Cost of Revenue, Total | 103.889 | 121.281 | 122 | 130 | 145 |
Bruto Peļņa | 177.461 | 182.177 | 183 | 212 | 241 |
Kopējie Darbības Izdevumi | 201.972 | 240.943 | 237 | 281 | 290 |
Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 86.447 | 94.618 | 100 | 123 | 122 |
Pētniecība un Attīstība | 19.389 | 23.065 | 19 | 29 | 25 |
Other Operating Expenses, Total | -7.753 | 1.979 | -4 | -1 | -2 |
Darbības Izdevumi | 79.378 | 62.515 | 68 | 61 | 96 |
Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -2.166 | -1.94 | -2 | 4 | -4 |
Neto Ienākumi Pirms Nodokļu Nomaksas | 77.212 | 60.575 | 66 | 65 | 92 |
Neto Ienākumi Pēc Nodokļu Nomaksas | 60.039 | 45.973 | 53 | 46 | 71 |
Neto Ienākumi Pirms Ārkārtas Posteņiem | 60.039 | 45.973 | 53 | 46 | 71 |
Neto Ienākumi | 60.039 | 45.973 | 53 | 46 | 71 |
Total Adjustments to Net Income | 0.001 | ||||
Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | 60.04 | 45.973 | 53 | 46 | 71 |
Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | 60.04 | 45.973 | 53 | 46 | 71 |
Atšķaidītie Neto Ienākumi | 60.04 | 45.973 | 53 | 46 | 71 |
Atšķaidītie Ienākumi par Akcijām | 65.2304 | 65.2674 | 65.3455 | 66.016 | 65.9838 |
Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | 0.92043 | 0.70438 | 0.81107 | 0.6968 | 1.07602 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 1.55 | 0 |
Atšķaidītā Normalizētā Peļņa par Akciju | 0.92043 | 0.72531 | 0.81353 | 0.70752 | 1.07602 |
- Ikgadējs
- Ceturkšņa
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Apgrozāmo Līdzekļu Kopsumma | 355.98 | 409.252 | 494.438 | 586.569 | 751.615 | 774 |
Nauda un Īstermiņa Ieguldījumi | 128.622 | 174.263 | 177.02 | 185.867 | 371.325 | 311 |
Nauda un Ekvivalenti | 128.622 | 174.263 | 177.02 | 185.867 | 371.325 | 311 |
Debitoru Parādu Kopsumma, Neto | 130.89 | 128.939 | 173.728 | 212.815 | 207.455 | 207 |
Accounts Receivable - Trade, Net | 118.348 | 118.191 | 156.042 | 197.651 | 194.018 | 180 |
Total Inventory | 88.906 | 95.794 | 132.338 | 173.76 | 159.823 | 237 |
Prepaid Expenses | 7.561 | 10.256 | 11.352 | 14.128 | 13.013 | 19 |
Other Current Assets, Total | 0.001 | -0.001 | -0.001 | |||
Total Assets | 695.196 | 757.201 | 1003.2 | 1335.69 | 1434.44 | 1992 |
Property/Plant/Equipment, Total - Net | 45.447 | 45.303 | 48.63 | 112.253 | 103.656 | 128 |
Property/Plant/Equipment, Total - Gross | 120.207 | 128.483 | 130.51 | 215.717 | 201.79 | 324 |
Accumulated Depreciation, Total | -74.76 | -83.18 | -81.88 | -103.464 | -98.134 | -196 |
Goodwill, Net | 104.023 | 104.023 | 186.055 | 315.869 | 290.209 | 741 |
Intangibles, Net | 116.015 | 118.646 | 192.654 | 260.047 | 250.787 | 313 |
Long Term Investments | 18.645 | 17.838 | 17.368 | 16.614 | 12.254 | 14 |
Note Receivable - Long Term | 1.156 | 0 | 0.003 | |||
Other Long Term Assets, Total | 53.93 | 62.139 | 64.055 | 44.335 | 25.92 | 22 |
Total Current Liabilities | 127.721 | 144.377 | 173.397 | 212.272 | 217.364 | 313 |
Accounts Payable | 38.133 | 47.457 | 54.764 | 41.461 | 51.236 | 56 |
Payable/Accrued | -0.001 | 0.001 | ||||
Accrued Expenses | 47.103 | 50.561 | 60.411 | 69.334 | 58.479 | |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 21.231 | 21.214 | 23 | ||
Other Current Liabilities, Total | 42.486 | 46.359 | 58.222 | 80.245 | 86.435 | 234 |
Total Liabilities | 131.958 | 148.59 | 301.023 | 460.184 | 444.403 | 621 |
Total Long Term Debt | 0 | 0 | 109.4 | 147.647 | 140.677 | 180 |
Deferred Income Tax | 1.759 | 1.621 | 14.78 | 28.884 | 32.838 | 73 |
Other Liabilities, Total | 2.478 | 2.592 | 3.446 | 71.381 | 53.524 | 55 |
Total Equity | 563.238 | 608.611 | 702.18 | 875.503 | 990.038 | 1371 |
Common Stock | 89.953 | 89.953 | 89.953 | 90.63 | 90.969 | 92 |
Retained Earnings (Accumulated Deficit) | 557.223 | 615.077 | 692.104 | 781.121 | 956.114 | 1063 |
Other Equity, Total | -83.938 | -96.419 | -79.877 | 3.752 | -116.547 | -50 |
Total Liabilities & Shareholders’ Equity | 695.196 | 757.201 | 1003.2 | 1335.69 | 1434.44 | 1992 |
Total Common Shares Outstanding | 64.7144 | 64.7144 | 64.7144 | 64.7144 | 65.2018 | 65.9838 |
Long Term Debt | 109.4 | 109.55 | 110 | 150 | ||
Capital Lease Obligations | 38.097 | 30.677 | 30 | |||
Additional Paid-In Capital | 59.502 | 266 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Apgrozāmo Līdzekļu Kopsumma | 851.273 | 694.254 | 784 | 774 | 842 |
Nauda un Īstermiņa Ieguldījumi | 422.068 | 278.552 | 359 | 311 | 349 |
Nauda un Ekvivalenti | 422.068 | 278.552 | 359 | 311 | 349 |
Debitoru Parādu Kopsumma, Neto | 237.214 | 221.377 | 217 | 226 | 249 |
Accounts Receivable - Trade, Net | 204.607 | 191.724 | 181 | 226 | 216 |
Total Inventory | 191.992 | 194.326 | 208 | 237 | 244 |
Other Current Assets, Total | -0.001 | -0.001 | |||
Total Assets | 1575.81 | 1409.61 | 1503 | 1992 | 2056 |
Property/Plant/Equipment, Total - Net | 126.05 | 125.751 | 124 | 128 | 126 |
Goodwill, Net | 302.381 | 297.524 | 304 | 741 | 746 |
Intangibles, Net | 259.79 | 257.747 | 257 | 313 | 309 |
Long Term Investments | 12.263 | 12.224 | 12 | 14 | 15 |
Other Long Term Assets, Total | 24.051 | 22.115 | 22 | 22 | 18 |
Total Current Liabilities | 246.435 | 263.719 | 289 | 313 | 298 |
Accounts Payable | 53.503 | 46.03 | 54 | 56 | 43 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 22.653 | 23.289 | 24 | 23 | 23 |
Other Current Liabilities, Total | 170.279 | 194.4 | 211 | 234 | 232 |
Total Liabilities | 493.496 | 390.115 | 413 | 621 | 601 |
Total Long Term Debt | 153.626 | 40.861 | 37 | 180 | 175 |
Long Term Debt | 110 | 0 | 0 | 150 | 150 |
Capital Lease Obligations | 43.626 | 40.861 | 37 | 30 | 25 |
Deferred Income Tax | 36.325 | 36.86 | 37 | 73 | 72 |
Other Liabilities, Total | 57.11 | 48.675 | 50 | 55 | 56 |
Total Equity | 1082.31 | 1019.5 | 1090 | 1371 | 1455 |
Common Stock | 90.969 | 90.969 | 91 | 92 | 92 |
Additional Paid-In Capital | 60.137 | 61.239 | 64 | 266 | 269 |
Retained Earnings (Accumulated Deficit) | 1016.15 | 964.324 | 1017 | 1063 | 1134 |
Other Equity, Total | -84.948 | -97.032 | -82 | -50 | -40 |
Total Liabilities & Shareholders’ Equity | 1575.81 | 1409.61 | 1503 | 1992 | 2056 |
Total Common Shares Outstanding | 65.2018 | 65.2018 | 65.2018 | 65.9838 | 65.9838 |
- Ikgadējs
- Ceturkšņa
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Neto ienākumi/Sākuma Līnija | 92.401 | 136.26 | 176.289 | 211.992 | 222.729 | 269 |
Nauda no Darbības | 139.072 | 168.932 | 155.005 | 211.807 | 279.047 | 353 |
Nauda no Darbības | 43.836 | 34.225 | 39.412 | 74.372 | 73.904 | 75 |
Bezskaidras Naudas Preces | -1.187 | 1.991 | -11.727 | 2.129 | -11.661 | 4 |
Cash Taxes Paid | 5.363 | 5.091 | 9.314 | 9.925 | 15.083 | 16 |
Samaksātie Procenti Naudā | 0.023 | 0.002 | 1.738 | 2.86 | 3.339 | 3 |
Izmaiņas Apgrozāmajā Kapitālā | 4.022 | -3.544 | -48.969 | -76.686 | -5.925 | 5 |
Nauda no Ieguldījumu Darbībām | -67.726 | -36.903 | -178.411 | -85.676 | -61.32 | -341 |
Kapitālie Izdevumi | -47.54 | -37.804 | -47.158 | -45.454 | -60.941 | -56 |
Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | -20.186 | 0.901 | -131.253 | -40.222 | -0.379 | -285 |
Nauda no Darbībām ar Finansēšanu | -81.152 | -81.053 | 19.342 | -119.205 | -22.723 | -82 |
Total Cash Dividends Paid | -80.893 | -80.893 | -90.6 | -97.803 | 0 | -98 |
Parādu Izsniegšana (Atkāpšanās), Neto | -0.259 | -0.16 | 109.942 | -21.402 | -22.723 | 16 |
Ārvalstu Valūtas Ietekme | 3.544 | -5.336 | 6.821 | 1.921 | -9.547 | 9 |
Neto Izmaiņas Naudā | -6.262 | 45.64 | 2.757 | 8.847 | 185.457 | -61 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 77.212 | 137.787 | 204 | 269 | 92 |
Cash From Operating Activities | 67.62 | 159.904 | 249 | 353 | 57 |
Cash From Operating Activities | 17.133 | 35.656 | 54 | 75 | 23 |
Non-Cash Items | -1.912 | -2.579 | -5 | 4 | 5 |
Cash Taxes Paid | 4.569 | 8.686 | 14 | 16 | 15 |
Changes in Working Capital | -24.813 | -10.96 | -4 | 5 | -63 |
Cash From Investing Activities | -18.266 | -34.637 | -45 | -341 | -14 |
Capital Expenditures | -18.266 | -34.137 | -44 | -56 | -14 |
Other Investing Cash Flow Items, Total | 0 | -0.5 | -1 | -285 | 0 |
Cash From Financing Activities | -5.17 | -223.759 | -227 | -82 | -6 |
Issuance (Retirement) of Debt, Net | -5.17 | -125.956 | -129 | 16 | -6 |
Foreign Exchange Effects | 6.559 | 5.719 | 10 | 9 | 2 |
Net Change in Cash | 50.743 | -92.773 | -13 | -61 | 39 |
Total Cash Dividends Paid | -97.803 | -98 | -98 | 0 |
Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
---|---|---|---|---|---|---|
SEB Investment Management AB | Investment Advisor | 7.55 | 4981775 | -6598 | 2022-12-31 | LOW |
Swedbank Robur Fonder AB | Investment Advisor/Hedge Fund | 6.84 | 4513290 | -1505315 | 2022-12-31 | LOW |
Invesco Advisers, Inc. | Investment Advisor | 5.75 | 3794067 | -41121 | 2022-12-31 | LOW |
ODIN Forvaltning AS | Investment Advisor | 4.5466 | 3000000 | 0 | 2022-12-31 | LOW |
Didner & Gerge Fonder AB | Investment Advisor | 3.8037 | 2509857 | 1528969 | 2022-12-31 | LOW |
Handelsbanken Kapitalförvaltning AB | Investment Advisor/Hedge Fund | 3.6075 | 2380357 | 17122 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.39 | 2236850 | 52787 | 2022-12-31 | LOW |
Lannebo Fonder AB | Investment Advisor/Hedge Fund | 3.2803 | 2164438 | 0 | 2022-12-31 | LOW |
Tredje AP Fonden | Pension Fund | 3.1 | 2045497 | 310124 | 2022-12-31 | LOW |
Första AP-Fonden | Pension Fund | 2.3926 | 1578713 | 1578713 | 2022-06-30 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 2.31 | 1524225 | -6599 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.86 | 1227298 | 59385 | 2022-12-31 | LOW |
TIN Fonder | Investment Advisor | 1.53 | 1009552 | -10412 | 2022-12-31 | MED |
Montanaro Asset Management Limited | Investment Advisor | 1.37 | 903978 | 219232 | 2022-12-31 | LOW |
M & G Investment Management Ltd. | Investment Advisor | 1.25 | 824797 | 0 | 2022-12-31 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 1.14 | 752215 | -39590 | 2022-09-30 | LOW |
Goldman Sachs Asset Management, L.P. | Investment Advisor | 1.0636 | 701784 | -154 | 2022-11-30 | LOW |
DNCA Investments | Investment Advisor | 0.9396 | 620000 | -50224 | 2022-12-31 | LOW |
Danske Bank Asset Management | Investment Advisor | 0.9353 | 617175 | 0 | 2023-01-31 | LOW |
Nordea Funds Oy | Investment Advisor | 0.9048 | 597007 | -5298 | 2022-12-31 | LOW |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com GroupTirgotāji
Ikmēneša aktīvie klienti
Ikmēneša ieguldījumu apjoms
Izņemts katru mēnesi
Treidinga kalkulators
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Biotage Company profile
Par Biotage
Biotage AB ir Zviedrijā bāzēts uzņēmums, kas izstrādā un pārdod sistēmas, palīgmateriālus un pakalpojumus dzīvības zinātņu jomā. Uzņēmuma klienti ir farmācijas un biotehnoloģiju uzņēmumi, pārtikas rūpniecības uzņēmumi un akadēmiskās iestādes. Uzņēmums piedāvā sistēmas un pakalpojumus trīs jomās: analītiskā ķīmija, organiskā ķīmija un rūpnieciskie sveķi. Biotage piedāvājums analītiskās ķīmijas jomā ietver palīgmateriālus ar saistītām lietojumprogrammām, lai ekstrahētu izvēlētās vielas no dažāda veida paraugiem. Uzņēmuma piedāvājums organiskās ķīmijas jomā ietver produktus farmācijas produktu izstrādei, kuru pamatā ir gan mazas molekulas, gan peptīdi, un tā piedāvājumu rūpniecisko sveķu jomā veido sveķi uz polimēru bāzes un pētniecības pakalpojumi, kuru rezultātā tiek izstrādāti un ražoti materiāli uz polimēru bāzes. 2013. gada 31. decembrī Sabiedrībai pilnībā piederēja 12 meitasuzņēmumi visā pasaulē.
Industry: | Medical Diagnostic & Testing Equipment |
Vimpelgatan 5
UPPSALA
UPPSALA 753 18
SE
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 500 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com